Sökning: onr:"swepub:oai:DiVA.org:uu-534377" > Identifying therape...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 07188naa a2200697 4500 | |
001 | oai:DiVA.org:uu-534377 | |
003 | SwePub | |
008 | 240704s2024 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:238684708 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5343772 URI |
024 | 7 | a https://doi.org/10.1038/s41467-024-46834-32 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:2386847082 URI |
040 | a (SwePub)uud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Smith-Byrne, Karlu Univ Oxford, Canc Epidemiol Unit, Oxford Populat Hlth, Oxford, England.4 aut |
245 | 1 0 | a Identifying therapeutic targets for cancer among 2074 circulating proteins and risk of nine cancers |
264 | 1 | b Springer Nature,c 2024 |
338 | a electronic2 rdacarrier | |
520 | a Circulating proteins can reveal key pathways to cancer and identify therapeutic targets for cancer prevention. We investigate 2,074 circulating proteins and risk of nine common cancers (bladder, breast, endometrium, head and neck, lung, ovary, pancreas, kidney, and malignant non-melanoma) using cis protein Mendelian randomisation and colocalization. We conduct additional analyses to identify adverse side-effects of altering risk proteins and map cancer risk proteins to drug targets. Here we find 40 proteins associated with common cancers, such as PLAUR and risk of breast cancer [odds ratio per standard deviation increment: 2.27, 1.88-2.74], and with high-mortality cancers, such as CTRB1 and pancreatic cancer [0.79, 0.73-0.85]. We also identify potential adverse effects of protein-altering interventions to reduce cancer risk, such as hypertension. Additionally, we report 18 proteins associated with cancer risk that map to existing drugs and 15 that are not currently under clinical investigation. In sum, we identify protein-cancer links that improve our understanding of cancer aetiology. We also demonstrate that the wider consequence of any protein-altering intervention on well-being and morbidity is required to interpret any utility of proteins as potential future targets for therapeutic prevention. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
700 | 1 | a Hedman, Åsau Pfizer Worldwide Res Dev & Med, External Sci & Innovat, Stockholm, Sweden.;Karolinska Inst, Dept Med, Stockholm, Sweden.4 aut |
700 | 1 | a Dimitriou, Mariosu Karolinska Institutet,Pfizer Worldwide Res Dev & Med, External Sci & Innovat, Stockholm, Sweden.;Karolinska Inst, Dept Med, Stockholm, Sweden.4 aut |
700 | 1 | a Desai, Trishnau Univ Oxford, Canc Epidemiol Unit, Oxford Populat Hlth, Oxford, England.4 aut |
700 | 1 | a Sokolov, Aleksandr V.u Uppsala universitet,Funktionell farmakologi och neurovetenskap4 aut0 (Swepub:uu)aleso209 |
700 | 1 | a Schiöth, Helgi B.u Uppsala universitet,Funktionell farmakologi och neurovetenskap4 aut0 (Swepub:uu)helgschi |
700 | 1 | a Koprulu, Mineu Univ Cambridge, MRC Epidemiol Unit, Cambridge, England.4 aut |
700 | 1 | a Pietzner, Maiku Univ Cambridge, MRC Epidemiol Unit, Cambridge, England.;Charite Univ Medizin Berlin, Berlin Inst Hlth, Computat Med, Berlin, Germany.;Queen Mary Univ London, Precis Healthcare Inst, London, England.4 aut |
700 | 1 | a Langenberg, Claudiau Univ Cambridge, MRC Epidemiol Unit, Cambridge, England.;Charite Univ Medizin Berlin, Berlin Inst Hlth, Computat Med, Berlin, Germany.;Queen Mary Univ London, Precis Healthcare Inst, London, England.4 aut |
700 | 1 | a Atkins, Joshuau Univ Oxford, Canc Epidemiol Unit, Oxford Populat Hlth, Oxford, England.4 aut |
700 | 1 | a Cortez Penha, Ricardou Int Agcy Res Canc IARC WHO, Genom Epidemiol Branch, Lyon, France.4 aut |
700 | 1 | a McKay, Jamesu Int Agcy Res Canc IARC WHO, Genom Epidemiol Branch, Lyon, France.4 aut |
700 | 1 | a Brennan, Paulu Int Agcy Res Canc IARC WHO, Genom Epidemiol Branch, Lyon, France.4 aut |
700 | 1 | a Zhou, Siruiu McGill Univ, Dept Human Genet, Montreal, PQ, Canada.4 aut |
700 | 1 | a Richards, Brent J.u McGill Univ, Dept Med Endocrinol, Montreal, PQ, Canada.;McGill Univ, Dept Human Genet, Montreal, PQ, Canada.;McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada.4 aut |
700 | 1 | a Yarmolinsky, Jamesu Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, England.4 aut |
700 | 1 | a Martin, Richard M.u Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, England.;Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, England.;Univ Bristol, Hosp Bristol & Weston NHS Fdn Trust, NIHR Bristol Biomed Res Ctr, Bristol, England.4 aut |
700 | 1 | a Borlido, Joanau Pfizer Inc, Canc Immunol Discovery, Pfizer Worldwide Res & Dev Med, San Diego, CA USA.4 aut |
700 | 1 | a Mu, Xinmeng J.u Pfizer Inc, Oncol Res Unit, Pfizer Worldwide Res & Dev Med, San Diego, CA USA.4 aut |
700 | 1 | a Butterworth, Adamu Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England.4 aut |
700 | 1 | a Shen, Xiau Univ Edinburgh, Usher Inst, MRC Human Genet Unit, Edinburgh, Scotland.4 aut |
700 | 1 | a Wilson, Jimu Univ Edinburgh, Usher Inst, MRC Human Genet Unit, Edinburgh, Scotland.4 aut |
700 | 1 | a Assimes, Themistocles L.u Stanford Univ, Div Cardiovasc Med, Stanford, CA USA.;Stanford Univ, Cardiovasc Inst, Sch Med, Stanford, CA USA.4 aut |
700 | 1 | a Hung, Rayjean J.u Sinai Hlth Syst, Lunenfeld Tanenbaum Res Inst, Prosserman Ctr Hlth Res, Toronto, ON, Canada.;Univ Toronto, Toronto, ON, Canada.4 aut |
700 | 1 | a Amos, Christopheru Baylor Med Coll, Inst Clin & Translat Res, Dept Med, Epidemiol Sect, Houston, TX USA.4 aut |
700 | 1 | a Purdue, Marku NCI, Div Canc Epidemiol & Genet, Rockville, MD USA.4 aut |
700 | 1 | a Rothman, Nathanielu NCI, Div Canc Epidemiol & Genet, Occupat & Environm Epidemiol Branch, Rockville, MD USA.4 aut |
700 | 1 | a Chanock, Stephenu NCI, Div Canc Epidemiol & Genet, Rockville, MD USA.4 aut |
700 | 1 | a Travis, Ruth C.u Univ Oxford, Canc Epidemiol Unit, Oxford Populat Hlth, Oxford, England.4 aut |
700 | 1 | a Johansson, Mattiasu Int Agcy Res Canc IARC WHO, Genom Epidemiol Branch, Lyon, France.4 aut |
700 | 1 | a Mälarstig, Andersu Pfizer Worldwide Res Dev & Med, External Sci & Innovat, Stockholm, Sweden.;Karolinska Inst, Dept Med, Stockholm, Sweden.4 aut |
710 | 2 | a Univ Oxford, Canc Epidemiol Unit, Oxford Populat Hlth, Oxford, England.b Pfizer Worldwide Res Dev & Med, External Sci & Innovat, Stockholm, Sweden.;Karolinska Inst, Dept Med, Stockholm, Sweden.4 org |
773 | 0 | t Nature Communicationsd : Springer Natureg 15:1q 15:1x 2041-1723 |
856 | 4 | u https://doi.org/10.1038/s41467-024-46834-3y Fulltext |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1881908/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-534377 |
856 | 4 8 | u https://doi.org/10.1038/s41467-024-46834-3 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:238684708 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy